Biblio Discovery — Demo Discovery Service

5 results for "David Forster"

Showing 1–5 · 1.24 seconds · RSS

  1. Journal Article Full text

    Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

    Roy S. Herbst; Edward B. Garon; Dong‐Wan Kim et al.

    Journal of Thoracic Oncology · 2021 · English · OpenAlex Scopus

    INTRODUCTION: In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in patients with previously treated, advanced NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50% and ≥1%. We report 5-year efficacy and safety follow-up for the…

  2. Journal Article Full text

    Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study

    Roy S. Herbst; Edward B. Garon; Dong‐Wan Kim et al.

    Journal of Clinical Oncology · 2020 · English · OpenAlex Scopus

    PURPOSE In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in previously treated, programmed death-ligand 1 (PD-L1)‒expressing advanced non‒small-cell lung cancer (NSCLC) in patients with a tumor proportion score (TPS) ≥ 50% and ≥ 1%. We report KEYNOTE-010…

  3. Journal Article Full text

    Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study

    Alvina Grace Lai; Laura Pasea; Amitava Banerjee et al.

    BMJ Open · 2020 · English · OpenAlex Scopus

    OBJECTIVES: To estimate the impact of the COVID-19 pandemic on cancer care services and overall (direct and indirect) excess deaths in people with cancer. METHODS: We employed near real-time weekly data on cancer care to determine the adverse effect of the pandemic on cancer services. We also used…

  4. Journal Article Full text

    Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

    Adrian Gerold Sacher; Patricia A. LoRusso; Manish R. Patel et al.

    New England Journal of Medicine · 2023 · English · OpenAlex Scopus

    Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity. In a phase 1 study, we evaluated divarasib administered orally once daily (at doses ranging from 50 to 400 mg) in patients who had advanced or metastatic solid tumors that harbor a KRAS…

  5. Journal Article Full text

    The evolution of lung cancer and impact of subclonal selection in TRACERx

    Alexander M. Frankell; Michelle Dietzen; Maise Al Bakir et al.

    Nature · 2023 · English · OpenAlex Scopus

    . Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the…